ZIAGEN

This brand name is authorized in United States. It is also authorized in Australia, Austria, Canada, Croatia, Cyprus, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, South Africa, Spain, Tunisia, Turkey, UK.

Active ingredients

The drug ZIAGEN contains one active pharmaceutical ingredient (API):

1	Abacavir UNII J220T4J9Q2 - ABACAVIR SULFATE
	Abacavir is a NRTI. It is a potent selective inhibitor of HIV-1 and HIV-2. Abacavir is metabolised intracellularly to the active moiety, carbovir 5'-triphosphate (TP). In vitro studies have demonstrated that its mechanism of action in relation to HIV is inhibition of the HIV reverse transcriptase enzyme, an event which results in chain termination and interruption of the viral replication cycle.
	Read more about Abacavir

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ZIAGEN Oral solution	MPI, EU: SmPC	European Medicines Agency (EU)
ZIAGEN Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J05AF06	Abacavir	J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AF Nucleoside and nucleotide reverse transcriptase inhibitors
Discover more medicines within J05AF06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	10294T, 10356C
CA	Health Products and Food Branch	02240357, 02240358
EE	Ravimiamet	1196119, 1196120
ES	Centro de información online de medicamentos de la AEMPS	99112001, 99112002
FI	Lääkealan turvallisuus- ja kehittämiskeskus	101995, 102006
FR	Base de données publique des médicaments	62070450, 68556562
GB	Medicines & Healthcare Products Regulatory Agency	44427, 44430
HK	Department of Health Drug Office	46236, 63701
IL	מִשְׂרַד הַבְּרִיאוּת	4210
IT	Agenzia del Farmaco	034499018, 034499020
JP	医薬品医療機器総合機構	6250014F1036
LT	Valstybinė vaistų kontrolės tarnyba	1006256, 1006257
NL	Z-Index G-Standaard	14255782
NL	Z-Index G-Standaard, PRK	135992, 136018
NZ	Medicines and Medical Devices Safety Authority	8479, 8480
PL	Rejestru Produktów Leczniczych	100095210, 100095227
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W65271001, W65272001
SG	Health Sciences Authority	11098P
TN	Direction de la Pharmacie et du Médicament	23013041H
TR	İlaç ve Tıbbi Cihaz Kurumu	8699522096107
US	FDA, National Drug Code	49702-221, 49702-222
ZA	Health Products Regulatory Authority	33/20.2.8/0464, 33/20.2.8/0465